Detailed 48 - week results
from a Phase 3 study evaluating the efficacy and safety of switching
from a regimen containing
abacavir, dolutegravir and lamivudine (600 / 50/300 mg)(ABC / DTG / 3TC) to Biktarvy, a once - daily single tablet regimen, in virologically suppressed adults with HIV.